{"id":"voriconazole-clinical-practice","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Visual disturbances (blurred vision, photopsia)"},{"rate":"10-20","effect":"Hepatotoxicity (elevated liver enzymes)"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Hallucinations"},{"rate":"1-5","effect":"QT prolongation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Voriconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This leads to depletion of ergosterol, a critical component of the fungal cell membrane, causing membrane instability and fungal cell death. It has broad-spectrum activity against many clinically important fungi including Aspergillus, Candida, and Cryptococcus species.","oneSentence":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:53.884Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Esophageal candidiasis"},{"name":"Candidemia in non-neutropenic patients"},{"name":"Serious Candida infections (intra-abdominal, bladder wall, kidney, peritonitis)"},{"name":"Scedosporium and Fusarium infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04238884","phase":"PHASE4","title":"Effectiveness and Efficiency of a Voriconazole Preemptive Genotyping Strategy","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-01-02","conditions":"Invasive Fungal Infections","enrollment":146}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":200,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Voriconazole clinical practice","genericName":"Voriconazole clinical practice","companyName":"Instituto de Investigación Hospital Universitario La Paz","companyId":"instituto-de-investigaci-n-hospital-universitario-la-paz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Esophageal candidiasis, Candidemia in non-neutropenic patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}